Small Molecules
8 September 2015
Wellstat Therapeutics Announces FDA Approval of XURIDEN™ to Treat Rare Pediatric Disorder Hereditary Orotic Aciduria (HOA)7 September 2015
Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program4 September 2015
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis4 September 2015
Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate With Potential for Rapid Onset of Effect4 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack4 September 2015
Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma2 September 2015
Innocoll AG Announces First Patient Dosed in the XaraColl MATRIX-1 Phase 3 Study for the Treatment of Postoperative Pain2 September 2015
Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study2 September 2015
TESARO Announces U.S. FDA Approval of VARUBI(TM) (rolapitant) for Nausea and Vomiting Associated With Cancer Chemotherapy2 September 2015
Positive Phase III Results Demonstrate Efficacy Of Antibiotic Medicine AVYCAZ™ (ceftazidime-avibactam) In Complicated Urinary Tract Infections2 September 2015
Zosano Pharma Completes Enrollment in Phase 1 Study for Microneedle Patch Delivery of Zolmitriptan for the Treatment of Migraine2 September 2015
Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia1 September 2015
Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator (SARM), for Acute Hip Fracture1 September 2015
Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain 8/31/151 September 2015
Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma31 August 2015
Lipocine Submits New Drug Application to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 102131 August 2015
Portage’s PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports